EFFECTIVENESS AND ADVERSE EFFECTS OF SEMAGLUTIDE IN THE TREATMENT OF OBESITY

A LITERATURE REVIEW

Authors

DOI:

https://doi.org/10.61164/rmnm.v9i1.3948

Keywords:

Semaglutide, Obesity, Adverse Effects, Effectiveness, Weight Loss

Abstract

Obesity is a chronic and complex disease that affects a large portion of the Brazilian population, causing significant physical, mental, and social impacts. It is often associated with comorbidities such as type 2 diabetes, hypertension, and cardiovascular diseases, and it compromises individuals' quality of life and overall well-being. In recent years, the use of semaglutide as a weight-loss medication has attracted considerable interest, although it is often employed in pursuit of rapid results and without appropriate supervision. Although semaglutide has been approved for the treatment of obesity, its use must be accompanied by specific clinical criteria and professional monitoring. This study aims, through an integrative literature review, to characterize the efficacy and adverse effects of semaglutide in the treatment of obesity. The present study is an integrative review of the scientific literature. Data collection was conducted in scientific databases of the Virtual Health Library (BVS). Inclusion criteria comprised studies published between 2019 and 2024, available in full text in Portuguese, English, or Spanish, and whose objectives were aligned with the research topic. Of the 65 articles initially identified, 10 were selected for full analysis after excluding those that did not meet the established criteria. Semaglutide has emerged as a promising pharmacological alternative in the treatment of obesity, providing significant reductions in body weight, body mass index (BMI), and waist-related measures, as well as improvements in cardiometabolic parameters. However, its use is associated with adverse events, mainly gastrointestinal, which can impact adherence to treatment. Long-term studies are essential to further substantiate its effects beyond the adult population.
Views: 1257Downloads: 294

Downloads

Download data is not yet available.

References

ABESO. Atualização das diretrizes para o tratamento Farmacológico da obesidade e do sobrepeso. Posicionamento Oficial da ABESO/ SBEM, 2010. Disponível em: <https://abeso.org.br/wp-content/uploads/2019/12/Atualizacao-das-Diretrizes.pdf>. Acesso em: 20 out. 2024.

ABESO. Mapa da obesidade no Brasil, 2024 Disponível em: https://abeso.org.br/obesidade-e-sindrome-metabolica/mapa-da-obesidade. Acesso em: 20 out. 2024.

AHMANN, A. J. et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, v. 41, n. 2, p. 258–266, 15 dez. 2017. Disponível em: https://diabetesjournals.org/care/article/41/2/258/30310/Efficacy-and-Safety-of-Once-Weekly-Semaglutide. Acesso em: 2 nov. 2024.

BALATA, M.; BECHER, M. U. Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis. BMC Cardiovascular Disorders, v. 24, n. 1, 26 out. 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11515153/. Acesso em: 02 jan. 2025.

BRASIL. Ministério da Saúde. Boletim epidemiológico: Cenário da obesidade no Brasil v 55, n. 7. Brasília, 2024. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/edicoes/2024/boletim-epidemiologico-volume-55-no-07.pdf. Acesso em: 20 out. 2024.

BRASIL. Ministério da Saúde. Sobrepeso e obesidade como problemas de saúde pública. 2022. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-brasil/eu-quero-ter-peso-saudavel/noticias/2022/sobrepeso-e-obesidade-como-problemas-de-saude-publica. Acesso em: 20 out. 2024.

CHAO, A. M. et al. Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine, v. 33, n. 3, dez. 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC9209591/. Acesso em: 23 out. 2024.

CORDEIRO, A. M. et al. Revisão sistemática: uma revisão narrativa. Rev Col Bras Cir, 34(6):428–31, 2007. Disponível em: https://doi.org/10.1590/S0100-69912007000600012. Acesso em: 23 out. 2024.

DICHTEL, L. E. The Glucagon‐Like Peptide‐1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis. Hepatology, v. 74, n. 4, p. 2290–2292, 10 ago. 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC8463414/. Acesso em: 23 out. 2024.

FRANCISCHI, R. P. P. et al. Obesidade: atualização sobre sua etiologia, morbidade e tratamento. Revista De Nutrição, 13(1), 17–28, 2000. Disponível em: https://www.scielo.br/j/rn/a/TGppS8yhnCMfkDJgmw9DTYm/?format=pdf&lang=pt. Acesso em: 23 out. 2024.

KOMMU, S; BERG, R.L. Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus:A systematic review and meta‐analysis of randomized controlled trials. Obesity Reviews, 23 jun. 2024. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/obr.13792. Acesso em: 20 jan. 2024.

Müllertz, A. L. O et al. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obes Rev Off J Int Assoc Study Obes V25, E5, 2024. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/obr.13717. Acesso em: 06 jan. 2025.

PEPE, R. B. et al. Posicionamento sobre o tratamento nutricional do sobrepeso e da obesidade: departamento de nutrição da Associação Brasileira para o estudo da obesidade e da síndrome metabólica (ABESO - 2022) 1. ed. São Paulo:Abeso,2022. Disponível em: https://abeso.org.br/wp-content/uploads/2022/11/posicionamento_2022-alterado-nov-22-1.pdf Acesso em: 2 nov. 2024.

QIN, W. et al. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial. Diabetes, Obesity and Metabolism, v. 26, n. 3, 2023. Disponível em: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15386. Acesso em: 06 jan. 2025.

QINGYANG, S. M. M et al. Pharmacotherapy for Adults with Overweight and obesity: a Systematic Review and Network meta-analysis of Randomised Controlled Trials. The Lancet, v. 399, n. 10321, p. 259–269, 2022. Disponível em: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01640-8/fulltext Acesso em: 20 fev. 2025.

RAMOS, G, M, F et al. Semaglutida como agonista do receptor glp-1: impactos no controle de peso e comorbidades associadas à obesidade. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 3, p. 1-20, 2020. Disponível em: https://bjihs.emnuvens.com.br/bjihs/article/view/2918/3129. Acesso em: 23 out. 2024

RUBINO, D. et al. Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. Obesity, v. 32, n. 7, p. 1268–1280, 2024. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/oby.24042. Acesso em: 20 fev. 2025.

SBCBM. Manual de Diretriz para o Enfrentamento da Obesidade na Saúde Suplementar Brasileira. Sociedade Brasileira de Cirurgia Bariátrica e Metabólica. 5.1 ed. São Paulo: SBCBM, 2024. Disponível em: https://www.sbcbm.org.br/wp-content/uploads/2024/07/MANUAL-DE-DIRETRIZ-PARA-O-ENFRENTAMENTO-DA-OBESIDADE-NA-SAUDE-SUPLEMENTAR-BRASILEIRA-V5.1.pdf. Acesso em: 21 out. 2024.

SILVA, J, M; Dionisio, G, H. Panorama sobre a obesidade: do viés cultural aos aspectos psíquicos. Rev. SBPH, São Paulo, v. 22, n. 2, p. 248-275, dez. 2019. Disponível em: <http://pepsic.bvsalud.org/scielo.php?script=sci_arttext&pid=S1516-08582019000300014&lng=pt&nrm=iso>. Acesso em: 26 dez. 2024.

SMITS, M. M; RAALTE, D. H. V. Safety of Semaglutide. Frontiers in Endocrinology, v. 12, jul. 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC8294388/. Acesso em: 20 fev. 2025.

TAN, H. C; DAMPIL, O. A; MARQUEZ, M. M. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies, v. 37, n. 2, p. 65-72, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36578889/. Acesso em: 02 jan. 2025.

TOMICKI, C. O uso do Ozempic (Semaglutida) no tratamento da obesidade – vantagens e vantagens. Revista Brasileira de Revisão de Saúde, v. 5, pág. e72874, 2024. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/72874. Acesso em: 15 nov. 2024.

WEGHUBER, D. et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine, v. 387, n. 24, p. 2245–2257, 2022. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC9997064/. Acesso em: 20 fev. 2025.

WILDING, J. P. H.; BATTERHAM, R. L.; CALANNA, S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, v. 384, n. 11, p. 989–1002, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33567185/. Acesso em: 20 fev. 2025.

YOKOTE, Koutaro et al. Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison. Advances in Therapy, 2024. Disponível em: https://link.springer.com/article/10.1007/s12325-024-02941-7. Acesso em: 20 fev. 2025.

Published

2025-05-15

How to Cite

Cavalcante, B., Lins, F., Coelho, C., & Galvão, J. (2025). EFFECTIVENESS AND ADVERSE EFFECTS OF SEMAGLUTIDE IN THE TREATMENT OF OBESITY: A LITERATURE REVIEW. REMUNOM, 9(1), 1-15. https://doi.org/10.61164/rmnm.v9i1.3948

Similar Articles

1-10 of 50

You may also start an advanced similarity search for this article.